First Page | Document Content | |
---|---|---|
![]() Date: 2016-08-16 03:53:14Medicine Clinical medicine Immunology Biology Immune system Monoclonal antibodies Biotechnology Glycoproteins Antibody Cancer immunotherapy Bispecific monoclonal antibody Phage display | Add to Reading List |
![]() | # 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,*,#, Stephen M. Shaw 1,*, Kim WiDocID: 1vdls - View Document |
![]() | Microsoft Word - ST64 Cancer Immunotherapy v1.0.docxDocID: 1uTyz - View Document |
![]() | FALL/WINTERUCSF Oncology Connection Oncologist Lawrence Fong, MD, is leading UCSF’s newly launched Cancer Immunotherapy ProgramDocID: 1tGAn - View Document |
![]() | Cancer Immunotherapy & Personalized Vaccines Alex Rubinsteyn Mount Sinai, Hammer LabDocID: 1tBVB - View Document |